Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Angiodynamics Inc (NQ: ANGO )

5.890 -0.250 (-4.07%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 437,388
Open 6.070
Bid (Size) 5.800 (1)
Ask (Size) 6.360 (1)
Prev. Close 6.140
Today's Range 5.835 - 6.105
52wk Range 5.260 - 11.38
Shares Outstanding 38,444,076
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AngioDynamics’ APEX-AV Trial Results Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism Presented at SCAI 2024 Scientific Sessions
From AngioDynamics, Inc.
Via Business Wire
Insiders Buying Zumiez And 3 Other Stocks
Although U.S. stocks closed little changed on Monday, there were a few notable insider trades. 
Via Benzinga

Performance

YTD
-26.65%
-26.65%
1 Month
-10.89%
-10.89%
3 Month
-0.84%
-0.84%
6 Month
-10.76%
-10.76%
1 Year
-34.26%
-34.26%

More News

Read More
Medical Devices Focused AngioDynamics Unveils Upbeat 2024 Financial Outlook, Stock Soars
Via Benzinga
Exposures Product Safety
ANGO Stock Earnings: AngioDynamics Misses EPS, Misses Revenue for Q3 2024
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics Receives 510(k) Clearance for AlphaVac F1885 System in Treatment of PE
From AngioDynamics, Inc.
Via Business Wire
Earnings Scheduled For April 4, 2024
Via Benzinga
AngioDynamics Resolves Decade-Long Patent Litigation With Becton, Dickinson In Settlement Agreement
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
AngioDynamics Announces Settlement of All Patent Litigation with C.R. Bard, Inc.
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics to Report Fiscal 2024 Third Quarter Financial Results on April 4, 2024
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics to Participate in a Fireside Chat at the Oppenheimer Virtual Healthcare MedTech & Services Conference
From AngioDynamics, Inc.
Via Business Wire
Hidden Gems: 7 Oversold Stocks Ready for a Major Rebound
Via InvestorPlace
AngioDynamics Announces Sale of PICC and Midline Product Portfolios to Spectrum Vascular for $45 Million
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics (ANGO) Stock Sinks As Market Gains: Here's Why
Via Talk Markets
Topics Stocks
Exposures US Equities
AngioDynamics Announces FDA 510(k) Clearance of Auryon XL Radial Access Catheter to Treat Peripheral Arterial Disease
From AngioDynamics, Inc.
Via Business Wire
Raymond James Maintains Outperform Rating for AngioDynamics: Here's What You Need To Know
Via Benzinga
Robinhood To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
Why AngioDynamics Stock Got Destroyed Today
Via The Motley Fool
Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
ANGO Stock Earnings: AngioDynamics Beats EPS, Misses Revenue for Q2 2024
Via InvestorPlace
Why Is Medical Devices-Focused AngioDynamics Stock Trading Lower Today?
Via Benzinga
US Stocks Poised To Extend New Year Slump As Focus Shifts To December Jobs Data: Analyst Sees S&P Testing 4,800 On This Condition
Via Benzinga
Topics Stocks
Exposures US Equities
AngioDynamics Reports Fiscal Year 2024 Second Quarter Financial Results; Revises Fiscal Year 2024 Guidance
From AngioDynamics, Inc.
Via Business Wire
Investor Sentiment Edges Lower Ahead Of Jobs Report; Nasdaq Tumbles For 5th Consecutive Day
Via Benzinga
Topics Stocks
Exposures US Equities
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.